Efficacy and safety of the oral direct thrombin inhibitor ximelagatran versus standard therapy (enoxaparin and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, international study (THRIVE Treatment)
Study identifier:SH-TPV-0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Efficacy and safety of the oral direct thrombin inhibitor ximelagatran versus standard therapy (enoxaparin and warfarin) for acute, symptomatic deep vein thrombosis with or without pulmonary embolism. A double-blind, international study (THRIVE Treatment)
Medical condition
venous thromboembolism
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Sept 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
